HUTCHMED (HCM) CEO Su Wei-guo reports major share and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo filed an initial ownership report showing a sizeable equity stake. He holds share options over 1,000,000 ordinary shares expiring in 2027 and another 1,000,000 ordinary shares expiring in 2028, plus additional options over American depositary shares with exercise prices between $22.09 and $35.21 per ADS and expirations from 2030 to 2031. Further options cover 1,405,767 ordinary shares expiring in 2034 and 1,493,435 ordinary shares expiring in 2035. He also directly owns 3,563,905 ordinary shares and 237,063 American depositary shares, and has indirect Long Term Incentive Plan awards over 39,862 and 169,977 ordinary shares held by a plan trustee. Each American depositary share represents 5 ordinary shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Su Wei-guo
Role
CEO and CSO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Share option (right to buy) | -- | -- | -- |
| holding | Long Term Incentive Plan awards granted on 03/13/2024 | -- | -- | -- |
| holding | Long Term Incentive Plan awards granted on 08/05/2024 | -- | -- | -- |
| holding | ordinary shares | -- | -- | -- |
| holding | American depositary shares | -- | -- | -- |
Holdings After Transaction:
Share option (right to buy) — 1,000,000 shares (Direct);
Long Term Incentive Plan awards granted on 03/13/2024 — 39,862 shares (Indirect, Held by Long Term Incentive Plan trustee);
Long Term Incentive Plan awards granted on 08/05/2024 — 169,977 shares (Indirect, Held by Long Term Incentive Plan trustee);
ordinary shares — 3,563,905 shares (Direct);
American depositary shares — 237,063 shares (Direct)
Footnotes (1)
- Each American depositary share represents 5 ordinary shares. The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options. The exercise price for the share option is GBP3.105 per ordinary share. The exercise price for the share option is GBP4.974 per ordinary share. The exercise price for the share option is denominated in United States dollar per American depositary share. The exercise of the share options granted is conditional upon the fulfilment of performance targets prescribed by the Board for the relevant performance periods (2023-2025, 2024-2026 and 2025-2027), as set out in the respective grant letters. For each grant, the number of share options that may become exercisable will be determined on the date of announcement of the annal results of the Company for the final financial year of the applicable performance period (i.e. the annual results announcements for the financial years ending December 31, 2025, 2026 and 2027, respectively). Vesting will occur two business days after the relevant results announcement. Any share options in respect of which the applicable performance targets are not met will lapse accordingly. The exercise price for the share option is HKD29.200 per ordinary share. The exercise price for the share option is HKD25.500 per ordinary share. 25% of Long Term Incentive Plan Awards vesting on each of March 13, 2025, March 13, 2026, March 13, 2027 and March 13, 2028. All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026.
FAQ
What does Su Wei-guo’s Form 3 filing show for HUTCHMED (HCM)?
The Form 3 shows CEO/CSO Su Wei-guo’s initial ownership in HUTCHMED, including direct ordinary shares, American depositary shares, multiple share option grants, and Long Term Incentive Plan awards held via a trustee, outlining his total reported equity exposure to the company.